Teyi Pharmaceutical Group Co Ltd (002728) — Working Capital to Net Assets Ratio
Teyi Pharmaceutical Group Co Ltd (002728) has a Working Capital to Net Assets ratio of 24.3% as of March 2026. Working capital of CN¥448.23 Million (current assets of CN¥891.85 Million minus current liabilities of CN¥443.63 Million) is measured against net assets of CN¥1.85 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Teyi Pharmaceutical Group Co Ltd (002728) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Teyi Pharmaceutical Group Co Ltd Working Capital to Net Assets (2009–2025)
This chart shows how Teyi Pharmaceutical Group Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2009 to 2025. As of March 2026, the ratio stands at 24.3%, reflecting working capital of CN¥448.23 Million against net assets of CN¥1.85 Billion CNY. For the complete balance sheet picture, see total assets of Teyi Pharmaceutical Group Co Ltd.
Annual Working Capital to Net Assets for Teyi Pharmaceutical Group Co Ltd (2009–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Teyi Pharmaceutical Group Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Teyi Pharmaceutical Group Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 21.9% | CN¥403.27 Million | CN¥1.84 Billion | CN¥857.60 Million | CN¥454.33 Million | ▲ +1.8 pp |
| 2024 | 20.1% | CN¥354.93 Million | CN¥1.76 Billion | CN¥950.95 Million | CN¥596.02 Million | ▼ -11.7 pp |
| 2023 | 31.8% | CN¥639.39 Million | CN¥2.01 Billion | CN¥1.11 Billion | CN¥465.77 Million | ▲ +30.4 pp |
| 2022 | 1.4% | CN¥19.62 Million | CN¥1.40 Billion | CN¥1.13 Billion | CN¥1.11 Billion | ▼ -15.7 pp |
| 2021 | 17.1% | CN¥215.61 Million | CN¥1.26 Billion | CN¥711.95 Million | CN¥496.34 Million | ▲ +12.4 pp |
| 2020 | 4.7% | CN¥51.00 Million | CN¥1.08 Billion | CN¥929.21 Million | CN¥878.22 Million | ▼ -9.3 pp |
| 2019 | 14.1% | CN¥162.00 Million | CN¥1.15 Billion | CN¥935.13 Million | CN¥773.13 Million | ▼ -12.0 pp |
| 2018 | 26.1% | CN¥289.77 Million | CN¥1.11 Billion | CN¥824.85 Million | CN¥535.08 Million | ▼ -8.4 pp |
| 2017 | 34.4% | CN¥359.26 Million | CN¥1.04 Billion | CN¥789.47 Million | CN¥430.22 Million | ▲ +39.5 pp |
| 2016 | -5.1% | CN¥-45.08 Million | CN¥886.57 Million | CN¥472.14 Million | CN¥517.22 Million | ▼ -10.7 pp |
| 2015 | 5.6% | CN¥45.43 Million | CN¥804.30 Million | CN¥637.57 Million | CN¥592.14 Million | ▼ -77.5 pp |
| 2014 | 83.1% | CN¥611.47 Million | CN¥735.64 Million | CN¥694.19 Million | CN¥82.72 Million | ▲ +14.6 pp |
| 2013 | 68.5% | CN¥239.75 Million | CN¥350.14 Million | CN¥336.25 Million | CN¥96.51 Million | ▼ -10.2 pp |
| 2012 | 78.7% | CN¥224.42 Million | CN¥285.34 Million | CN¥321.13 Million | CN¥96.70 Million | ▲ +3.6 pp |
| 2011 | 75.0% | CN¥169.14 Million | CN¥225.51 Million | CN¥226.84 Million | CN¥57.71 Million | ▲ +7.8 pp |
| 2010 | 67.2% | CN¥114.76 Million | CN¥170.81 Million | CN¥196.68 Million | CN¥81.92 Million | ▲ +24.3 pp |
| 2009 | 42.9% | CN¥44.23 Million | CN¥103.18 Million | CN¥130.71 Million | CN¥86.47 Million | — |